Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
作者:
主题词
腺癌, 透明细胞(Adenocarcinoma, Clear Cell);老年人(Aged);抗肿瘤药(Antineoplastic Agents);癌, 子宫内膜样(Carcinoma, Endometrioid);化学疗法, 辅助(Chemotherapy, Adjuvant);无病生存(Disease-Free Survival);女(雌)性(Female);人类(Humans);输注, 胃肠外(Infusions, Parenteral);中年人(Middle Aged);肿瘤分期(Neoplasm Staging);肿瘤, 残余(Neoplasm, Residual);肿瘤, 囊性, 黏液性和浆液性(Neoplasms, Cystic, Mucinous, and Serous);肿瘤, 腺和上皮(Neoplasms, Glandular and Epithelial);卵巢肿瘤(Ovarian Neoplasms);紫杉酚(Paclitaxel);预后(Prognosis);比例危险度模型(Proportional Hazards Models);回顾性研究(Retrospective Studies);存活率(Survival Rate);时间因素(Time Factors)
DOI
10.1016/j.ygyno.2016.10.003
PMID
27726923
发布时间
2021-12-21
- 浏览36

Gynecologic oncology
484-489页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文